In December 2025, Peijia Medical announced that the Companyreceivedaconfirmation letter from NMPA confirming its acceptance of the registrationapplicationof TaurusNXT Non-glutaraldehyde Crosslinked Dry-tissue TAVRsystem. TaurusNXT is a third-generation TAVR system internally developedbytheCompany.It incorporates patented non-glutaraldehyde bio-tissue crosslinkingtechnologythatremoves the main source of valve calcification which is the primary causeof prostheticvalve degeneration. This technology is designed to enhance thedurabilityandbiocompatibility of the prosthetic aortic valve (“PAV”).
Moreover, compared to traditional dry tissue technologies that useglycerin,theSystem adopts an ultra-low temperature vacuum freeze-dryingtechnology.Thisapproach helps maintain the physical integrity of the valve tissue whileenablingthePAV to be pre-loaded into the delivery catheter system(“DCS”). TheDCSofTaurusNXT has also been upgraded with both retrievability and steerabilityfeatures,which assist physicians in guiding the PAV to the target implant positionmoreeasily,thereby further improving procedural safety.
